# Pfizer Wins ~$10B Bidding War for GLP-1 Biotech Metsera

> ma · REPORTED · 2025-10-15

Pfizer acquired Metsera, an obesity-focused biotech developing GLP-1 receptor agonists including MET-097i currently in Phase II trials, in a deal worth up to $10 billion. The acquisition followed an intense bidding war with Novo Nordisk, which made three separate acquisition attempts.

About Pfizer: Metsera is a clinical-stage biotech developing next-generation GLP-1 receptor agonist therapies for obesity and metabolic disease, with multiple injectable and oral candidates in its pipeline.

- Company: Pfizer
- Sector: therapeutics
- Primary source: https://www.bioxconomy.com/partnering/bioxconomy-s-top-10-m-a-deals-of-2025

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.